Henry Ford Health

Henry Ford Health Scholarly Commons
Public Health Sciences Articles

Public Health Sciences

5-11-2021

Aspirin, ibuprofen, and reduced risk of advanced colorectal
adenoma incidence and recurrence and colorectal cancer in the
PLCO Cancer Screening Trial
Kenechukwu Chudy-Onwugaje
Wen-Yi Huang
L. Joseph Su
Mark P. Purdue
Christine C. Johnson
Henry Ford Health, cjohnso1@hfhs.org

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/
publichealthsciences_articles

Recommended Citation
Chudy-Onwugaje K, Huang WY, Su LJ, Purdue MP, Johnson CC, Wang L, Katki HA, Barry KH, and Berndt SI.
Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and
colorectal cancer in the PLCO Cancer Screening Trial. Cancer 2021.

This Article is brought to you for free and open access by the Public Health Sciences at Henry Ford Health
Scholarly Commons. It has been accepted for inclusion in Public Health Sciences Articles by an authorized
administrator of Henry Ford Health Scholarly Commons.

Authors
Kenechukwu Chudy-Onwugaje, Wen-Yi Huang, L. Joseph Su, Mark P. Purdue, Christine C. Johnson,
Lingxiao Wang, Hormuzd A. Katki, Kathryn Hughes Barry, and Sonja I. Berndt

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
publichealthsciences_articles/268

Original Article

Aspirin, Ibuprofen, and Reduced Risk of Advanced Colorectal
Adenoma Incidence and Recurrence and Colorectal Cancer in
the PLCO Cancer Screening Trial
2
Kenechukwu Chudy-Onwugaje, MBBS, MPH, MS1; Wen-Yi Huang, PhD, MSPH
; L. Joseph Su, PhD, MPH3;
2
4
2
Mark P. Purdue, PhD ; Christine C. Johnson, PhD ; Lingxiao Wang, PhD ; Hormuzd A. Katki, PhD2;
Kathryn Hughes Barry, PhD, MPH5,6; and Sonja I. Berndt, PharmD, PhD2

BACKGROUND: Studying the differential impact of aspirin and other nonsteroidal anti-inflammatory drugs across the stages of colorectal
neoplasia from early adenoma to cancer is critical for understanding the benefits of these widely used drugs. METHODS: With 13 years
of follow-up, the authors prospectively evaluated the association between aspirin and ibuprofen use and incident distal adenoma (1221
cases), recurrent adenoma (862 cases), and incident colorectal cancer (CRC; 2826 cases) among men and women in the population-based
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. With multivariable-adjusted models, odds ratio (ORs) and 95% confidence
intervals (CIs) for adenoma incidence and recurrence and hazard ratios (HRs) and 95% CIs for incident CRC were determined. RESULTS:
The authors observed a significantly reduced risk of incident adenoma with ibuprofen use (≥30 vs <4 pills per month: OR, 0.76 [95% CI,
0.60-0.95]; Ptrend = .04), particularly advanced adenoma (OR, 0.48 [95% CI, 0.28-0.83]; Ptrend = .005). Among those with a previous adenoma detected through screening, aspirin use was associated with a decreased risk of advanced recurrent adenoma (≥30 vs <4 pills per
month: OR, 0.56 [95% CI, 0.36-0.87]; Ptrend = 0.006). Both aspirin (HR, 0.88 [95% CI, 0.81-0.96]; Ptrend <.0001) and ibuprofen use (HR, 0.81
[95% CI, 0.70-0.93); Ptrend = 0.003) ≥30 versus <4 pills per month were significantly associated with reduced CRC risk. CONCLUSIONS: In
this large prospective study with long-term follow-up, a beneficial role for not only aspirin, but also ibuprofen, in preventing advanced adenoma and curbing progression to recurrence and cancer among older adults was observed. Cancer 2021;0:1-11. © 2021 American Cancer
Society. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
KEYWORDS: aspirin, colorectal cancer, ibuprofen, incident adenoma, recurrent adenoma.

INTRODUCTION
Colorectal cancer (CRC), the second leading cause of cancer-related deaths in the United States, exerts a significant
human and financial burden and is poised to remain a major health challenge in the new decade.1-3 With the rising
costs of health care and known barriers to screening,4 there is growing interest in the use of appropriate chemoprevention strategies to reduce the burden of CRC in the general population.5,6 Chronic inflammation has been implicated
in the process of colorectal tumorigenesis, and nonsteroidal anti-inflammatory drugs (NSAIDs) have been identified
in preclinical and clinical studies to have a protective effect against colorectal tumors.7-11 The mechanism of NSAID
chemoprevention against tumor proliferation is not completely understood but is thought to partly be related to its
inhibition of the cyclooxygenase (COX) enzyme.12,13 NSAID-induced antagonism of the COX isoforms, COX-1
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and COX-2, prevents the conversion of arachidonic
acid to prostaglandins, which are important mediators
of inflammation. COX-independent mechanisms have
also been proposed for the anticarcinogenic effects of
NSAIDs.14-16 Although CRC is thought to develop
over time from precursor lesions along the adenoma-
carcinoma pathway,17 it is unclear whether NSAIDs
act preferentially in the early stages of this sequence to
prevent tumor initiation or in the later stages to delay
progression. A better understanding of the differential
impact of NSAIDs on the clinical stages of colorectal
tumorigenesis will help inform the benefits of these
widely used drugs and guide the development of an appropriate framework for chemoprevention in a general
population.
Prospective observational studies have shown a
consistent reduction in colorectal cancer risk with aspirin use.18,19 Although the Aspirin in Reducing Events
in the Elderly (ASPREE) trial showed no benefit after
a few years of follow-up,20 raising new questions about
aspirin’s efficacy, especially in the elderly population,
evidence from earlier randomized controlled trials with
colorectal cancer as a secondary end point and longer follow-up has shown a reduction in risk with aspirin use.11 Fewer studies have evaluated non-aspirin
NSAIDs, such as ibuprofen, one of the most commonly
used non-aspirin NSAIDs, and most have grouped all
non-aspirin NSAIDs together without regard for pharmacological differences.21 Randomized trials of aspirin
and other NSAIDs among those with a history of adenoma have also largely reported a decreased incidence
of recurrent adenoma,22,23 but the long-term benefit is
unclear with some studies reporting an increased risk
of recurrence during the posttrial follow-up.9,24,25 Few
population-based studies have prospectively evaluated
the risk of incident and recurrent adenoma,26 and many
retrospective case-
control studies have had methodological challenges related to selection and recall bias.
In this prospective study, we examined the association of aspirin and ibuprofen with colorectal adenoma incidence, adenoma recurrence, and colorectal
cancer in a large cohort of men and women followed
in the Prostate, Lung, Colorectal and Ovarian (PLCO)
Cancer Screening Trial to gain a better understanding
of the population impact of NSAIDs on the different
stages of colorectal tumorigenesis. Participants randomized to the screening arm of the trial were assigned to
be endoscopically evaluated at baseline and after 3 to 5
years, allowing for a robust prospective assessment of
2

the association of NSAID use and incident adenoma
without selection or recall bias, and recurrence was
evaluated using follow-up data collected on endoscopies over 10 years. We evaluated study outcomes with
respect to the use of 2 nonselective COX inhibitors: aspirin, which binds irreversibly to COX and ibuprofen,
a reversible COX inhibitor.27,28
MATERIALS AND METHODS
Study Design

This is a prospective study of participants in the PLCO
Cancer Screening Trial, which is a randomized, multicenter trial designed to evaluate the impact of screening
on cancer-related mortality for malignancies arising in the
prostate, lungs, ovaries, colon, and rectum.29 As described
previously,30 a total of 154,952 men and women between
55 and 74 years of age were enrolled at 10 sites across
the United States between 1993 and 2001 and were randomized to either the intervention arm and underwent
cancer screening, or to the control arm and received usual
medical care. Participants completed a self-administered
risk factor questionnaire at baseline, and information was
collected on demographics, medical history, and medication use, including NSAIDs. The study was approved by
the human subjects review boards at the National Cancer
Institute and at the 10 study centers, and all participants
provided written informed consent.
Screening Examinations and Outcome
Data Collection

Of 77,447 participants randomized to the intervention arm of the PLCO trial, 64,655 (96.4%) underwent
CRC screening with flexible sigmoidoscopy at baseline
and 39,443 of those with a baseline screen had a second sigmoidoscopy at either the third (T3) or fifth (T5)
year after enrollment.31 Those with a positive screen
were sent to their usual health care providers for followup and 80.5% had a diagnostic intervention.31 Trained
staff reviewed all available medical records related to
the ensuing workup and outcomes were recorded based
on pathology reports. Participants in both arms of the
trial were actively followed for cancer incidence by each
of the 10 study sites through 2011. In 2011, data collection transitioned to follow-up at a centralized data
center through medical record review (2012-2013) and
cancer registry linkage; approximately 19,000 participants declined further follow-up during the re-consent
process. All colorectal cancer cases were histologically
confirmed through medical record review and/or via
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linkage to cancer registries. The present study included
data on cancer incidence through 2014.
Study Population

Similar to what we reported previously,32 participants
who completed the baseline questionnaire, had data on
NSAID use, and no history of Crohn’s disease, ulcerative colitis, familial polyposis, or Gardner’s syndrome
were included in these analyses. Further exclusions for
each specific outcome of interest are briefly described
below.
Incident distal colorectal adenoma

To examine the association with incident adenoma, we
conducted a nested case-control study. This analysis was
restricted to participants in the intervention arm with an
adequate flexible sigmoidoscopy (insertion ≥50 cm with
≥90% of mucosa visualized) at baseline that did not reveal any abnormalities or suspicious findings in the distal
colon and rectum (ie, negative baseline trial screen), and
had an adequate T3/T5 follow-up flexible sigmoidoscopy screen. We further excluded participants who had
a diagnosis of CRC before the T3/T5 screening or a self-
reported history of colorectal polyps at baseline. Cases
were those who had a negative baseline trial screen and
discovered to have adenoma in the distal colon or rectum
at T3/T5. Controls were those with negative trial screens
for adenoma at both baseline and T3/T5. In total, there
were 1221 incident distal colorectal adenoma cases (806
men and 415 women) and 19,626 controls (10,699 men
and 8927 women).
Recurrent colorectal adenoma

For recurrent adenoma, we conducted a case-
control
study. This analysis included participants in the intervention arm who had an adenoma at baseline and at least
1 follow-up endoscopy within the 10-year period after
baseline. The majority of subjects were part of a study
nested within the PLCO Trial known as the Study of
Colonoscopy Utilization (SCU),33 and we also included
recurrent adenoma cases diagnosed as part of the trial (ie,
those with an adenoma on both the baseline and T3/T5
trial endoscopy screens). We excluded participants who
had a history of colorectal cancer before diagnosis of a
recurrent adenoma or a self-reported history of colorectal
polyps at baseline. We defined cases as those with a baseline adenoma that were found to have an adenoma on
any later surveillance screen, whereas controls were those
with an adenoma diagnosis at baseline but no evidence
of adenoma on any surveillance colonoscopy during the
Cancer  
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following 10 years. After exclusions, there were 862 recurrent adenoma cases (614 men and 248 women) and 877
controls (499 men and 378 women).
Incident colorectal cancer

To evaluate the association with colorectal cancer, we conducted a cohort study. This analysis included participants
randomized to either the intervention or control arm
of the trial. Participants were followed from the time of
completion of the baseline questionnaire to the date of
CRC diagnosis, death, loss to follow-up, or December 31,
2014, whichever occurred first. Of the 127,454 included
participants, 2826 were diagnosed with colorectal cancer
over the median follow-up period of 13 years.
Exposure Assessment

NSAID use was evaluated based on participant responses
to 4 NSAID-related questions on the baseline questionnaire. Two questions asked if participants had regularly
used aspirin or aspirin-containing products and/or ibuprofen or ibuprofen-
containing products in the 12
months before screening. Those who reported regular
use of either product were asked 2 additional questions
about the usual number of pills taken in the preceding
12 months, and response options were as follows: 1 per
day, ≥2 per day, 1 per week, 2 per week, 3 to 4 per week,
<2 per month, and 2 to 3 per month. For the present
analysis, we converted responses into the number of pills
taken per month as described previously34 and created
separate variables for aspirin and ibuprofen use as follows:
<4 per month (including those reporting irregular use),
4 to 29 per month, and ≥30 per month. We also created
a variable for the combined use of aspirin and ibuprofen
and categorized this as follows: <4 per month (including
irregular use), 4 to 29 per month, 30 to 59 per month,
and ≥60 per month. We collapsed the 2 most frequent
use groups (30-59 per month and ≥60 per month) into 1
(≥30 per month) for aspirin use and ibuprofen use individually because of small sample sizes.
Statistical Methods

Descriptive analyses were performed to evaluate the association between characteristics at baseline, exposure
and outcomes. For the risk of incident and recurrent
adenoma, logistic regression was used to estimate odds
ratios (ORs) and corresponding 95% confidence intervals (CIs). For the colorectal cancer analysis, we created inverse propensity score weights to improve the
representativeness of the analytic cohort for incident
CRC and account for potential bias from the loss of
3
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TABLE 1. Characteristics of PLCO Cancer Screening Trial Participants in the Colorectal Cancer Analyses by
NSAID Use
Pattern of Aspirin and Ibuprofen Use

Age, mean (IQR), y
Male, No. (%)
White, No. (%)
Intervention arm, No. (%)
Family history of colorectal cancer, No. (%)
BMI, mean (IQR), kg/m2
Physical activity >3 h/wk, No. (%)
Cigarette smoking, No. (%)
Current
Former
History of, No. (%)
Cardiovascular diseasesa
Arthritis
Osteoporosis
Diabetes mellitus

No Regular Use (n = 49,254)

Aspirin Only (n = 40,847)

Ibuprofen Only (n = 15,610)

Combined Use
(n = 21,743)

63.1 (8.7)
24,178 (49.1)
42,029 (85.3)
25,430 (51.6)
4890 (9.9)

63.8 (8.8)
24,493 (60.0)
36,576 (89.5)
21,096 (51.6)
3907 (9.6)

62.0 (8.3)
5539 (35.5)
13,900 (89.0)
8121 (52.0)
1552 (9.9)

62.5 (8.6)
10,528 (48.4)
19,370 (89.1)
11,053 (50.8)
2155 (9.9)

27.0 (5.6)
5054 (10.3)

27.3 (5.5)
4267 (10.4)

27.8 (6.3)
1449 (9.3)

27.8 (5.9)
2083 (9.6)

5204 (10.6)
19,432 (39.5)

4457 (10.9)
18, 966 (46.4)

1766 (11.3)
6523 (41.8)

2447 (11.3)
10,605 (48.8)

15,646 (31.8)
15,706 (31.9)
2538 (5.2)
3399 (6.9)

19,933 (48.8)
13,929 (34.1)
1660 (4.1)
3848 (9.4)

5162 (33.1)
7937 (50.8)
1016 (6.5)
1032 (6.6)

9110 (41.9)
9873 (45.4)
1161 (5.3)
1801 (8.3)

Abbreviations: BMI, body mass index; IQR, interquartile range; NSAID, nonsteroidal anti-inflammatory drugs; PLCO, Prostate, Lung, Colorectal, and Ovarian.
a
Coronary artery disease, heart attack, hypertension, and stroke.

some participants to follow-up during the re-consent
process while transitioning to a central data collection
system.35 Using Cox proportional hazards regression
models, we estimated hazard ratios (HRs) and 95% CIs
for the risk of incident CRC with NSAID use. With <4
pills per month as the reference category for all analyses,
we constructed overall and sex-stratified models for the
respective outcomes of interest. The impact of multiple
potential confounders of the relationship between colorectal tumorigenesis and NSAID use were evaluated
(eg, physical activity) and only those that changed the
β coefficient for NSAID use by ≥10% were included in
final multivariable regression models.36 All regression
models included the following covariates: sex, age at
baseline or screening (for CRC analyses, age was the underlying time metric, and we adjusted for calendar year
at baseline), study center at enrollment, race, family
history of CRC, smoking status, and body mass index
(BMI) at baseline. We additionally adjusted for study
year of screening (T3 or T5) in the incident adenoma
analyses, number of follow-up colonoscopies and follow-up time from baseline endoscopy in the recurrent
adenoma analyses, and trial arm in the colorectal cancer
analyses. Separate analyses were performed for aspirin
(controlling for ibuprofen use), ibuprofen (controlling
for aspirin use), and the combined use of both medications. Additional analyses were conducted evaluating
aspirin use only and ibuprofen use only; findings were
similar to the results with mutual adjustment and therefore not presented.
4

To evaluate the association with increasing frequency of NSAID use, we estimated P values for trend
assuming an ordinal variable (ie, 0, 1, 2) for the multilevel
frequency categories of use. We also performed separate
analyses by anatomic site (proximal colon, distal colon, or
rectum), adenoma subtype (advanced or nonadvanced),
CRC stage (IV vs I to III), and participant’s age at enrollment (55-64 vs >65 or 55-69 vs >70). An adenoma was
considered to be advanced if it had one of the following
features: ≥1 cm in size, villous histology, or high-grade
dysplasia.37 A 2-tailed P value of <.05 was considered to
be statistically significant for all analyses.
RESULTS
Characteristics of the Study Population

Among the 127,454 eligible subjects with NSAID data
in the PLCO Cancer Screening Trial, the mean age at
baseline was 63 years, 50.8% of the subjects were male,
and the mean BMI was 27.3 kg/m2. The majority of
participants (88%) were non-Hispanic White. Ten percent of the study population had a family history of
CRC, and 10.9% were current smokers. No regular use
of NSAIDs was reported in 39% of the population,
whereas regular use of aspirin (only) and ibuprofen
(only) was recorded in 32% and 12% of them, respectively, and regular use of both aspirin and ibuprofen was
recorded in 17% of the population (Table 1). Among
the PLCO Trial participants with a negative baseline
screen and adequate T3/T5 screen, incident adenoma
Cancer  
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TABLE 2. Characteristics of PLCO Trial Participants in the Incident and Recurrent Adenoma Analyses by
Case and Control Status
Incident Adenoma
Characteristic
Age, mean (IQR), y
Male, No. (%)
White, No. (%)
Family history of colorectal cancer,
No. (%)
BMI in kg/m2, mean (IQR)
Physical activity >3 h/wk, No. (%)
Cigarette smoking, No. (%)
Current
Former
History of, No. (%)
Cardiovascular diseasesa
Arthritis
Osteoporosis
Diabetes mellitus

Recurrent Adenoma

Cases (n = 1221)

Controls (n = 19,626)

Cases (n = 862)

Controls
(n = 877)

62.4 (8.6)
806 (66.0)
1095 (89.7)
125 (10.2)

62.7 (8.3)
10,699 (54.5)
17,187 (87.6)
1691 (8.6)

63.3 (7.7)
614 (71.2)
786 (91.2)
106 (12.3)

63.1 (8.4)
499 (56.9)
836 (95.3)
105 (12.0)

27.6 (5.7)
261 (21.4)

27.1 (5.4)
4587 (23.4)

27.9 (5.6)
192 (22.3)

27.4 (5.6)
192 (21.9)

136 (11.1)
566 (46.4)

1053 (5.4)
8076 (41.1)

129 (15.0)
437 (50.7)

125 (14.3)
415 (47.3)

440 (36.0)
363 (29.7)
30 (2.5)
88 (7.2)

6859 (34.9)
6630 (33.8)
742 (3.8)
1204 (6.1)

314 (36.4)
265 (30.7)
20 (2.3)
59 (6.8)

310 (35.3)
298 (34.0)
22 (2.5)
68 (7.8)

Abbreviations: BMI, body mass index; IQR, interquartile range; PLCO, Prostate, Lung, Colorectal, and Ovarian.
a
Coronary artery disease, heart attack, hypertension, and stroke.

TABLE 3. Aspirin/Ibuprofen Use and the Risk of Incident Colorectal Adenoma in the PLCO Cancer Screening
Trial
NSAID Use (Times/
mo)
Aspirinb
<4
4 to <30
≥30
Ptrend
Ibuprofenb
<4
4 to <30
≥30
Ptrend
Combined use
<4
4 to <30
30 to <60
≥60
Ptrend

Incident Adenoma Overall
Controls

Cases

OR (95% CI)

11,979
2682
4965

743
152
326

16,172
1664
1790

9934
3488
3967
2237

a

Advanced

Nonadvanced
Cases

OR (95% CI)a

1.00
0.69 (0.47-1.03)
0.86 (0.65-1.13)
.07

370
76
166

1.00
0.87 (0.67-1.12)
0.95 (0.78-1.15)
.48

253
20
14

1.00
0.76 (0.48-1.21)
0.48 (0.28-0.83)
.005

511
52
49

1.00
0.97 (0.72-1.30)
0.87 (0.64-1.18)
.29

157
45
64
21

1.00
0.77 (0.55-1.08)
0.84 (0.62-1.13)
0.53 (0.33-0.84)
.008

312
110
129
61

1.00
0.95 (0.76-1.18)
0.90 (0.73-1.11)
0.82 (0.62-1.09)
.13

Cases

OR (95% CI)

1.00
0.87 (0.72-1.04)
0.92 (0.80-1.06)
.12

181
29
77

1027
106
88

1.00
0.98 (0.79-1.21)
0.76 (0.60-0.95)
.04

623
225
253
120

1.00
0.97 (0.83-1.14)
0.88 (0.75-1.02)
0.79 (0.64-0.97)
.01

a

Abbreviations: BMI, body mass index; CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drugs; OR, odds ratio; PLCO, Prostate, Lung, Colorectal,
and Ovarian.
a
The OR and 95% CI were calculated by using unconditional logistic regression and adjusted for study center, race, sex, family history of colorectal cancer, smoking
history, BMI, age at the T3/T5 flexible sigmoidoscopy screen, and the study year of the repeat flexible sigmoidoscopy screen (T3 or T5).
b
Aspirin use is adjusted for ibuprofen use and vice versa.

cases were more likely to be male, have a family history
of CRC, be current or former smokers compared to controls, and were less likely to receive >3 hours of physical activity per week compared to controls (Table 2).
Among PLCO Trial participants with adenoma at baseline and information on follow-up surveillance endoscopies, recurrent adenoma cases were more likely to be
male and non-White when compared to those without
a recurrence (Table 2).
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Incident Distal Colorectal Adenoma

Regular use of ibuprofen was associated with a significant
reduction in the risk of incident distal colorectal adenoma
overall (≥30 vs <4 pills per month: OR, 0.76 [95% CI,
0.60-0.95]; Ptrend = .04; Table 3). The protective association was stronger for advanced adenoma (≥30 vs <4 pills
per month: OR, 0.48 [95% CI, 0.28-0.83]; Ptrend = .005)
with no significant risk observed for nonadvanced adenoma (≥30 vs <4 pills per month: OR, 0.87 [95% CI,
5
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TABLE 4. Aspirin/Ibuprofen Use and the Risk of Recurrent Colorectal Adenoma in the PLCO Cancer
Screening Trial
NSAID Use (Times/
mo)

Recurrent Adenoma Overall

Advanced

Nonadvanced

Controls

Cases

OR (95% CI)a

Cases

OR (95% CI)a

Cases

OR (95% CI)a

553
126
198

544
109
209

1.00
0.87 (0.64-1.20)
0.90 (0.69-1.17)
.47

154
19
39

1.00
0.55 (0.31-0.97)
0.56 (0.36-0.87)
.006

390
90
170

1.00
0.99 (0.71-1.39)
1.05 (0.79-1.38)
.63

736
77
64

737
68
57

1.00
0.87 (0.59-1.27)
1.15 (0.75-1.77)
.75

185
10
17

1.00
0.55 (0.26-1.15)
1.31 (0.68-2.54)
.52

552
58
40

1.00
0.94 (0.63-1.40)
1.07 (0.67-1.72)
.79

462
166
178
71

478
139
183
62

1.00
0.81 (0.61-1.08)
0.87 (0.66-1.14)
0.91 (0.59-1.38)
.29

136
24
32
20

1.00
0.49 (0.29-0.82)
0.50 (0.31-0.80)
1.09 (0.58-2.04)
.06

342
115
151
42

1.00
0.92 (0.68-1.26)
1.03 (0.77-1.37)
0.83 (0.52-1.33)
.69

b

Aspirin
<4
4 to <30
≥30
Ptrend
Ibuprofenb
<4
4 to <30
≥30
Ptrend
Combined use
<4
4 to <30
30 to <60
≥60
Ptrend

Abbreviations: BMI, body mass index; CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drugs; OR, odds ratio; PLCO, Prostate, Lung, Colorectal,
and Ovarian.
a
The OR and 95% CI were calculated by using unconditional logistic regression and adjusted for study center, race, sex, family history of colorectal cancer, smoking
history, BMI, age at baseline, number of follow-up colonoscopies, and follow-up time from baseline endoscopy.
b
Aspirin use is adjusted for ibuprofen use and vice versa.

0.64-1.18]; Ptrend = .29; Pheterogeneity for advanced vs nonadvanced =
.06). Similarly, combined use of aspirin and ibuprofen was
associated with a significantly lower risk of incident distal
adenoma overall (≥60 vs <4 pills per month: OR, 0.79
[95% CI, 0.64-0.97]; Ptrend = .01), with greater benefit
for advanced adenoma (≥60 vs <4 pills per month: OR,
0.53 [95% CI, 0.33-0.84]; Ptrend = .008) and no significant protection against nonadvanced adenoma (≥60 vs
<4 pills per month: OR, 0.82 [95% CI, 0.62-1.09]; Ptrend
= .13; Pheterogeneity for advanced vs nonadvanced = .18). Although
there was no evidence of an association between aspirin
use and the risk of incident distal colorectal adenoma
overall (≥30 vs <4 pills per month: OR, 0.92 [95% CI,
0.80-1.06]; Ptrend = .12), we observed some evidence of
a trend between increased aspirin use and reduced risk of
advanced adenoma (≥30 vs <4 pills per month: OR, 0.86
[95% CI, 0.65-1.13]; Ptrend = .07). No significant differences in risk were observed by anatomic site (ie, distal
colon vs rectum) with the use of aspirin, ibuprofen, or
both combined (Pheterogeneity > .10 for all).

Ptrend = .006; Table 4). This beneficial association was
not observed for nonadvanced recurrent adenoma (≥30
vs <4 pills per month: OR, 1.05 [95% CI, 0.79-1.38];
Ptrend = .63), and the difference in risk between advanced
and nonadvanced adenoma was statistically significant
(Pheterogeneity = .001). Although there was no significant association for the highest category, combined use
of both aspirin and ibuprofen was also associated with
a decreased risk of advanced recurrent adenoma for
most use categories (ie, 4 to <30 [OR, 0.49 (95% CI,
0.29-0.82)] and 30 to <60 pills per months [OR, 0.50
(95% CI, 0.31-0.80)]). No protective associations were
observed for combined use with regard to nonadvanced
recurrent adenoma (Ptrend = .69), and the difference
between advanced and nonadvanced adenoma was significant (Pheterogeneity = .047). There were no significant
associations between ibuprofen use and the risk of recurrent adenoma (Table 4). No significant risk differences
were observed by anatomic site (ie, proximal colon, distal
colon, and rectum).

Recurrent Colorectal Adenoma

Colorectal Cancer Incidence

There was no significant association between the use of
aspirin and the risk of recurrent adenoma overall (≥30
vs <4 pills per month: OR, 0.90 [95% CI, 0.69-1.17];
Ptrend = .47), but aspirin use was significantly associated
with a reduced risk of advanced recurrent adenoma (≥30
vs <4 pills per month: OR, 0.56 [95% CI, 0.36-0.87];

We observed a decrease in the risk of colorectal cancer
overall with increased use of aspirin (≥30 vs <4 pills per
month: HR, 0.88 [95% CI, 0.81-0.96]; Ptrend <.0001),
ibuprofen (≥30 vs <4 pills per month: HR, 0.81 [95%
CI, 0.70-0.93]; Ptrend = .003) and the combined use of
both medications (≥60 vs <4 pills per month: HR, 0.79
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TABLE 5. Aspirin/Ibuprofen Use and the Risk of Colorectal Cancer in the PLCO Cancer Screening Trial

NSAID Use
(Times/mo)
Aspirinb
<4
4 to <30
≥30
Ptrend
Ibuprofenb
<4
4 to <30
≥30
Ptrend
Combined use
<4
4 to <30
30 to <60
≥60
Ptrend

Colorectal Cancer
Overall

Proximal Colon

Distal Colon

Rectum

Controls

Cases

HR (95% CI)a

Cases

HR (95% CI)a

Cases

HR (95% CI)a

Cases

HR (95% CI)a

75,905
16,084
32,639

1817
309
700

1.00
0.79 (0.70-0.89)
0.88 (0.81-0.96)
<.0001

970
169
378

1.00
0.80 (0.68-0.94)
0.89 (0.79-1.00)
.008

504
78
180

1.00
0.73 (0.57-0.93)
0.82 (0.69-0.98)
.003

315
57
133

1.00
0.86 (0.64-1.14)
0.97 (0.79-1.19)
.39

101,210
11,432
11,986

2375
231
220

1.00
0.92 (0.80-1.05)
0.81 (0.70-0.93)
.003

1272
133
112

1.00
0.98 (0.82-1.18)
0.75 (0.62-0.91)
.0091

643
57
62

1.00
0.84 (0.64-1.11)
0.87 (0.66-1.13)
.23

423
40
42

1.00
0.88 (0.63-1.23)
0.92 (0.67-1.27)
.38

61,849
22,035
25,437
15,307

1545
432
550
299

1.00
0.79 (0.71-0.88)
0.85 (0.77-0.94)
0.79 (0.69-0.89)
<.0001

824
240
293
160

1.00
0.82 (0.71-0.94)
0.84 (0.73-0.96)
0.77 (0.65-0.92)
.0003

422
113
145
82

1.00
0.76 (0.62-0.94)
0.84 (0.69-1.02)
0.81 (0.64-1.04)
.02

275
73
105
52

1.00
0.75 (0.58-0.98)
0.91 (0.73-1.15)
0.82 (0.60-1.10)
.15

Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio; NSAID, nonsteroidal anti-inflammatory drugs; PLCO, Prostate, Lung, Colorectal,
and Ovarian.
a
HR and 95% CI calculated by Cox proportional hazards regression adjusted for study center, race, sex, family history of colorectal cancer, smoking history, BMI,
trial arm, and calendar year at baseline (age was the underlying time metric).
b
Aspirin use is adjusted for ibuprofen use and vice.

[95% CI, 0.69-0.89]; Ptrend <.0001; Table 5). Overall,
there were no significant differences by anatomic location between NSAID use and cancer risk (Pheterogeneity
> .10). With aspirin use, we observed a significant inverse association for cancers in the proximal (≥30 vs <4
pills per month: HR, 0.89 [95% CI, 0.79-1.00]; Ptrend
= .008) and distal colon (≥30 vs <4 pills per month:
HR, 0.82 [95% CI, 0.69-0.98]; Ptrend = .003). Similarly,
there was a significant protective effect observed with
the combined use of both medications for cancers in
the proximal (≥60 vs <4 pills per month: HR, 0.77
[95% CI, 0.65-0.92]; Ptrend = .0003) and distal colon
(≥60 vs <4: HR, 0.81 [95% CI, 0.64-1.04]; Ptrend =
.02). Ibuprofen use was also associated with a decreased
cancer risk in the proximal colon (≥30 vs <4: HR, 0.75
[95% CI, 0.62-0.91]; Ptrend = .0091) but not in the distal colon (≥30 vs <4: HR, 0.87 [95% CI, 0.66-1.13];
Ptrend = .23). No significant associations were observed
with rectal cancer for either aspirin or ibuprofen, but
the sample size was smaller. We observed no significant
differences in the relative risk of CRC with NSAID use
when stratifying by stage of CRC, participant’s age at
enrollment, or trial arm.
DISCUSSION
In this large prospective study of participants in a cancer screening trial followed for cancer incidence over a
median duration of 13 years, we identified beneficial
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protective associations between NSAIDs and the risk of
incident distal colorectal adenoma, recurrent colorectal adenoma, and CRC. First, we found that ibuprofen
and combined use of aspirin and ibuprofen were significantly associated with a decreased risk of incident
distal adenoma overall, and we observed a more pronounced protective effect for advanced than nonadvanced incident distal adenoma. Second, we observed
that although there was no association between NSAID
use and the risk of recurrent adenoma overall, aspirin
and the combined use of both medications were significantly associated with a decreased risk of advanced
recurrent adenoma, whereas there was no significant
protection against nonadvanced recurrent adenoma.
Finally, we observed significant inverse associations between the use of aspirin and ibuprofen and the combined use of both medications and the risk of incident
CRC. Taken together, these findings show the chemopreventive benefits of NSAIDs against the development
and recurrence of colorectal adenoma, particularly advanced adenoma, and the progression to colorectal cancer. To our knowledge, this is one of the first studies to
prospectively evaluate the impact of NSAIDs across the
stages of colorectal tumorigenesis in the context of a
colorectal cancer screening trial with long-term followup. Although the numbers of advanced adenoma cases
were relatively small in some categories and replication
is needed to confirm that our findings are not due to
7
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chance, our study is one of the first prospective studies to report a beneficial role of ibuprofen in reducing
the risk of advanced incident adenoma and CRC in a
general population.
Data from experimental and clinical studies have
shown that NSAIDs suppress colorectal tumor formation.7,8 However, evidence for the role of NSAIDs in
preventing the initiation of colorectal adenoma in a
population with no history of adenoma is sparse with
many studies reporting the association with prevalent adenoma,38 where it is difficult to assess how long the adenoma was present before endoscopy and whether NSAID
use occurred before or after development of adenoma.
In the present study, participants without a history of
polyps at baseline who had a negative baseline endoscopy were prospectively followed to see if they developed adenoma after 3 or 5 years, allowing us to capture
incident cases. We found that use of ibuprofen and the
combined use of ibuprofen and aspirin were associated
with a significantly reduced risk of incident distal adenoma overall, particularly advanced adenoma, suggesting
that they may curb progression more than prevent initiation. Consistent with our findings for ibuprofen, we
observed a trend toward a reduced risk of advanced incident distal adenoma with increased aspirin use (Ptrend =
.07). Among adenomas, the advanced ones are of utmost clinical concern because of their greater likelihood
of progression to CRC. Analyses of participants in the
Nurses’ Health Study and Health Professional Follow-up
Study provide support for the protective role of aspirin
against incident adenoma, because regular aspirin use
was associated with a reduced risk of incident distal colorectal adenoma among women with a previous negative
endoscopy (OR, 0.73; 95% CI, 0.60-0.89),26 whereas a
borderline association was observed for men (OR, 0.65;
95% CI, 0.42-1.02).39 Few studies have specifically evaluated advanced adenoma. Consistent with our study, a
study among participants in the Nurses’ Health Study
and Health Professional Follow-up Study reported a reduced prevalence of high-risk adenoma, including both
advanced adenoma and those with >3 adenomas on
their initial screen, with both non-aspirin NSAID use
and aspirin use.40
In our study, we observed that aspirin use was associated with a significantly decreased risk of recurrence of
advanced adenoma but not nonadvanced recurrent adenoma or recurrent adenoma overall. Our finding for advanced recurrent adenoma is consistent with the findings
of a meta-analysis of 5 published randomized controlled-
trials (RCTs), where subjects with previously resected
8

adenomas who received daily aspirin were observed to
have a decreased risk of advanced adenoma (RR, 0.70;
95% CI, 0.55-0.88) and adenoma overall (RR, 0.83;
95% CI, 0.73-0.94).22 Although we did not observe a
significant reduction in overall adenoma risk, this may
be explained by our use of irregular aspirin use (<4 pills
per month) as the reference category. The baseline PLCO
survey did not have response options on NSAID use that
would have allowed for the creation of a purely null category as a reference group and the inclusion of irregular
users with never users may have attenuated our results.
Nonetheless, we posit that our use of the “irregular use”
category as the referent may be more reflective of real-
world use of NSAIDs as there are relatively few never-
users. In a survey of adults between 45 and 75 years of
age in the United States, approximately three-quarters
reported regular or previous aspirin use.41
In this analysis, there was no association between
ibuprofen use and the risk of recurrent adenoma overall or advanced recurrent adenoma over a 10-year period.
Although there are no comparable ibuprofen studies that
have evaluated this association, 3 RCTs have evaluated
the effect of other non-aspirin NSAIDs, celecoxib and
rofecoxib, on recurrent colorectal adenoma in the general population.9,42,43 Compared to placebo, daily use
of these COX-2 inhibitors reduced the risk of recurrent
adenoma overall and advanced recurrent adenoma over a
3-year follow-up period in subjects drawn from a general
population who had histologically confirmed adenomas
removed before the start of the study; however, increased
risks of adenoma were observed for the treatment groups
in the post-trial follow-up period,9,24,25 suggesting the
benefit may not be long-lasting. In contrast to aspirin
where the inhibition of COX is irreversible because of covalent binding, the binding of ibuprofen and other non-
aspirin NSAIDs to COX is reversible.27 Over an extended
period, some individuals may give up taking non-aspirin
NSAIDs, such as ibuprofen or selective COX-2 inhibitors due to their adverse effects, especially at higher doses,
leading to reduced benefit. Notably, COX-2 selective inhibitors have been found to be associated with a greater
risk of cardiovascular adverse effects, and rofecoxib has
since been withdrawn from the market for this reason.44
Consistent with findings from multiple observational
studies,18,19,21,45 we found an inverse association between
the use of aspirin, ibuprofen, and combined use of both
medications and the risk of CRC. In a meta-analysis of 30
observational studies (15 case-control and 15 cohort), a
27% reduction in CRC risk was reported with regular use
of aspirin (RR = 0.73; 95% CI, 0.67-0.79).45 Similarly,
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a 20% reduction in CRC risk was observed with non-
aspirin NSAIDs in a meta-analysis of 10 prospective studies (RR, 0.80; 95% CI, 0.72-0.88), although ibuprofen
was not evaluated specifically.21 Although we observed
greater benefit for CRC with increasing frequency of use
for analyses of ibuprofen, for aspirin, we observed a similar protective effect regardless of frequency. It is possible
that for aspirin, which binds irreversibly to COX, an increased frequency of use does not provide greater benefit,
whereas for ibuprofen, which binds reversibly to COX
and acts as a competitive inhibitor of arachidonic acid
oxygenation, may provide greater protection when taken
more frequently.
Randomized clinical trials with CRC as a secondary
end point have yielded more mixed results on the association between aspirin and CRC. In the ASPREE trial
among elderly populations in Australia and the United
States (100 mg of aspirin daily)20 and the US Physicians’
Health Study (325 mg of aspirin on alternate days),46
administration of aspirin did not reduce the risk of colorectal cancer over a treatment and follow-up period of
4.7 and 5 years, respectively. However, analyses of the
Women’s Health Study (100 mg of aspirin on alternate
days)47 and 2 smaller trials in the United Kingdom of
a higher daily dose of aspirin (300-1200 mg) administered over a period of 1 to 9 years48,49 found an inverse
association between allocation to aspirin and the risk of
CRC, consistent with findings from review articles.50,51
Notably, these protective effects were observed only after
a follow-up period of 10 years, as further confirmed in a
meta-analysis of 4 RCTs with a mean duration of scheduled aspirin treatment of approximately 6 years and a
median follow-up period of 18 years.11 This is close to
the median follow-up period of 13 years in our study and
may account for the time needed for the completion of
the multistep process of tumorigenesis in the natural history of CRC development.52
The meta-analysis11 also found that aspirin preferentially reduced the risk of cancer in the colon, especially
proximal colon, but not in the rectum. Although we observed a significant inverse association between NSAIDs
and the risk of cancer in the colon, but not in the rectum,
we did not detect statistically significant heterogeneity
in the associations by anatomic subsite. Similar to our
findings, heterogeneity of CRC risk was not observed by
anatomic site with NSAID use in a recent study within
the European Prospective Investigation into Cancer and
Nutrition (EPIC) cohort.53 Other published studies,
however, have been inconsistent in their observed differences in cancer risk based on tumor location.26,50,54-56
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The association of ibuprofen with CRC risk has not been
previously explored in a general population, but many observational studies have evaluated the risk of CRC with
use of other non-aspirin NSAIDs, and they have largely
observed a protective association.21 In a nested case-
control study using a government insurance database of
patients 65 years and older, nonselective NSAIDs, as well
as rofecoxib and celecoxib, were both found to be protective against the development of CRC.57
In this large, population-based, prospective study
with long-term follow-up, we were able to comprehensively evaluate the risks associated with not only aspirin, but also ibuprofen, across the stages of colorectal
tumorigenesis. Our incident adenoma analyses also
benefited from drawing participants from the screening arm of the trial, such that subjects were screened
regardless of health care coverage or indication, limiting selection bias. Regarding limitations of our study,
as the PLCO used flexible sigmoidoscopy for screening,
we were unable to evaluate the association of NSAID
use with proximal adenoma. Additionally, some controls in the incident adenoma analysis may have had
undetected proximal adenoma. Assuming that NSAIDs
are protective for proximal adenoma, this could have
led to an underestimate of the magnitude of the association between NSAIDs and incident adenoma. There
are also several limitations of the NSAIDs data. We had
only limited self-reported data on frequency of aspirin
and ibuprofen use. We did not collect information on
the use of other, less commonly used, NSAIDs, such
as naproxen or selective COX-2 inhibitors, which may
have provided a fuller assessment of risk. Information
on drug dose was not collected, so we were unable to
explore differences between low-
dose and high-
dose
aspirin use. Additionally, we only evaluated NSAID
use at baseline, limiting our ability to conclude if the
observed benefits were because of NSAID use at baseline or during follow-up. Although aspirin and ibuprofen data were available in follow-up questionnaires in
the PLCO trial, when we evaluated the correlation of
NSAID use patterns over time, we found that 77% of
those who were regular aspirin users at baseline reported
continued regular use in a follow-up questionnaire approximately 9.2 years later. Given the strong correlation
with the baseline data and limited follow-up time after
the questionnaire, the potential contribution to the
analysis seemed small; as such, we did not incorporate
the follow-up data into the present analysis. Although
some underreporting of NSAID use by self-report has
been noted in other studies, reporting accuracy tends to
9
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improve with more frequent and regular use.58 Because
information on NSAID use was obtained prospectively
in this study, any misclassification of NSAID use because of inaccurate reporting is likely to be nondifferential, leading most likely to an attenuation of the
protective effects of aspirin and ibuprofen.
In conclusion, in this large cancer screening trial
cohort, we observed a protective effect of aspirin and
ibuprofen on the risk of incident distal advanced colorectal adenoma, recurrent advanced colorectal adenoma,
and colorectal cancer, suggesting that these widely used
NSAIDs play a role among older adults in preventing the
progression of colorectal adenoma to cancer, interrupting the transformation to malignant disease. Although we
cannot be certain if the benefits observed for NSAIDs are
because of baseline use, ongoing use, or both, our prospective, population-based study supports and extends the
findings from randomized trials, providing evidence for a
long-term benefit of aspirin and ibuprofen among individuals of average risk. The protection offered by these
medications was shown not only for colorectal cancer, but
also adenoma and advanced adenoma, which are important precursor lesions and targets for prevention. Because
our sample size for advanced adenoma was limited, replication of these findings is needed. Future studies should
also balance the potential for medication-related adverse
effects as well as life expectancy when assessing the use of
NSAIDs for chemoprevention recommendations.
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